Key result
PVC@HMP-1 catheters outperform heparin in rats, maintaining 28-day patency without inflammation or mortality.
Why the study?
Heparin use in extracorporeal circulation catheters can cause side effects and does not completely inactivate certain coagulation factors, motivating development of heparin-free alternatives.
Hypothesis-generating for hemocompatible catheters; leaves open human translation pending clinical trials.
. The rapid recovery of coagulation factors after operation further confirmed its superiority over heparin, which would not completely inactivate the activity of those coagulation factors (XII, XI, IX and VIII). In addition, the PVC@HMP-1 catheters remain patent after being implanted in rats for 28 days without apparent inflammation and mortality complications. The anticoagulation PVC tubes could be used to construct various systemic and integrative anticlotting biomedical devices, which would dramatically reduce the introduction of heparin into blood circulation, thus preventing side effects and promoting the development of heparin-free treatment.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied this question. PVC@HMP-1 catheters vs. heparin was evaluated on Catheter patency, inflammation, and mortality. PVC@HMP-1 catheters remained patent in rats for 28 days without inflammation or mortality, and showed rapid recovery of coagulation factors confirming superiority over heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Journal of Materials Chemistry B